Shared on 01 Nov 25
Fair value Increased 1.45%Illumina's analyst price target has increased modestly, with the average rising from $111.95 to $113.58. Analysts cite stronger operational performance and revenue growth, even as the company faces ongoing sector and regional challenges.
Shared on 04 Sep 25
Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks
Illumina’s unchanged analyst price target reflects a balance between optimism for sector-leading EPS growth and resilience in consumables, and caution around persistent funding pressures, regulatory risks, and macroeconomic uncertainties, resulting in a maintained fair value of $111.95. Analyst Commentary Mixed quarterly performance prompted both positive and conservative price target adjustments, with solid earnings and guidance raises offset by ongoing academic funding pressures.
Shared on 07 May 25
Fair value Decreased 1.93%Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks
Shared on 30 Apr 25
Fair value Decreased 3.00%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 1.97%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 4.17%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 2.94%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 1.59%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 0.66%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 21%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 2.37%Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.